Background: Injectable dulaglutide (D) and oral semaglutide (S) are the two commonly used glucagon like peptide 1 receptor analogues (GLP1-RA), with minimal real-life comparative evidence in Type 2 Diabetes (T2D). Thus, a retrospective, multi-center, cohort study was conducted to compare them.
No takes yet. Share an insight, caveat, or question.
Sinha et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: